Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
roseofungin
- Development stage
- Phase 1
- Lead developer
- Scientific and Production Center of Microbiology and Virology
- Modality
- Small Molecules
- Administration
- Vaginal
01
Overview
CanProFem-AK is an antifungal drug containing roseofungin 100 mg as the active pharmaceutical ingredient, formulated as vaginal suppositories. It is being developed for the treatment of candidiasis (fungal infections). The drug was developed at the Research and Production Center of Microbiology and Virology. A Phase 1 clinical trial has been conducted to evaluate its safety and tolerability in healthy female volunteers.
- Brand names
- CanProFem-AK
- Other names
- Roseofungin
02
Targets
Ergosterol
Beyond the preview
Go deeper on roseofungin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on roseofungin.